
    
      This multicentre randomised controlled clinical trial conducted in China include phase I
      study and phase II study.

      Phase I study: to get the maximum tolerated dose of anlotinib when combined with Docetaxel.

      Phase II study: to compare the effectiveness and safety of Anlotinib Plus Docetaxel in
      patients of EGFR wild-type Advanced Non-squamous Non-small Cell Lung Cancer.
    
  